Key facts
- Takeda Pharmaceutical is seeking to include its dengue vaccine in India's national immunization program.
- The dengue vaccine is named Qdenga.
- Qdenga received regulatory approval in India last month.
- The vaccine is expected to launch commercially in early 2027.
- The initial commercial launch will be in the private market.
Japanese drugmaker Takeda Pharmaceutical is pursuing the inclusion of its dengue vaccine, Qdenga, into India's National Immunisation Programme. The vaccine recently received regulatory approval in India last month. Takeda anticipates a commercial launch for Qdenga in early 2027, with initial distribution planned for the private market. This strategic move aims to broaden access to the dengue vaccine across India's population, following its successful regulatory clearance.